In one paragraphArticle in Science translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Dimitra KaragkouniBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0009-0007-3961-3399 Anna FalangaImmunohematology and Transfusion Medicine, ASST Papa Giovanni XXIII, Bergamo 24127, Italy.ORCID 0000-0002-5007-3457 Marina MarchettiImmunohematology and Transfusion Medicine, ASST Papa Giovanni XXIII, Bergamo 24127, Italy.ORCID 0000-0001-9036-960X Laura RussoImmunohematology and Transfusion Medicine, ASST Papa Giovanni XXIII, Bergamo 24127, Italy.ORCID 0000-0003-0018-7090 Simon ManthaMemorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Thita ChiasakulCenter of Excellence in Translational Hematology, Division of Hematology, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.ORCID 0000-0002-0443-1751 Marc CarrierUniversity of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6 Canada.ORCID 0000-0001-8296-2972 Philip S WellsUniversity of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON K1H 8L6 Canada.ORCID 0000-0002-8657-8326 Robert E GersztenBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-6767-7687 Robert FlaumenhaftBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0001-8004-9688 Daniel HuiDepartment of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Ioannis S VlachosBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.ORCID 0000-0002-8849-808X Jeffrey I ZwickerMemorial Sloan Kettering and Weill Cornell Medical College, New York, NY 10065, USA.ORCID 0000-0001-5810-6893 Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4MOrgan Specific ProjectU54HL165440 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI HONG, YOUNG-KWON, SINGHAL, DHRUV · 2022 to 2025
$5.8MBiomarkers and mechanisms in cancer associated thrombosisU01HL143365 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CHAIKOF, ELLIOT, FLAUMENHAFT, ROBERT C · 2018 to 2022
$4.3MPan-Cancer characterization of 3’UTR somatic mutations controlling tumor immune evasionR01CA258776 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Ioannis Vlachos · 2022 to 2026
$2.9MFunctional genetics of tissue factor in bleeding and thrombotic riskDP5OD028129 · OD · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SCHULMAN, SOL · 2019 to 2023
$2.2MGenetic architecture of tissue factor expressionR01HL175060 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Sol Schulman · 2024 to 2026
$2.0MTRAINING GRANT FOR RESEARCH IN BLOOD COMPONENTST32HL007437 · NHLBI · TUFTS MEDICAL CENTER · PI FURIE, BRUCE · 1985 to 1997
–NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA258776NHLBI NIH HHS R01 HL175060NHLBI NIH HHS T32 HL007437NHLBI NIH HHS U01 HL143365NHLBI NIH HHS U54 HL165440NIH HHS DP5 OD028129
6 · The paper itselfAbstract
Thrombosis remains a major cause of morbidity and mortality in patients with cancer. Existing risk models fail to reliably predict venous thromboembolism (VTE), underscoring the need for more accurate predictive models. In this study, we conducted a high-throughput proteomic analysis of 1105 plasma proteins in peripheral blood samples from patients with newly diagnosed lung or gastric cancer who were prospectively monitored for VTE development. Using a Bayesian probabilistic machine learning approach, we developed a predictive model incorporating 11 protein biomarkers and five clinical parameters (age, sex, history of VTE, body mass index, and hemoglobin), which outperformed the standardly used Khorana prediction score [
Indexed as
Endothelium, VascularInterleukin-17NeoplasmsProteomicsThrombosisAnimalsBayes TheoremFemaleFibrin Fibrinogen Degradation ProductsHumansMaleMiceMiddle AgedVenous ThromboembolismFibrin Fibrinogen Degradation Productsfibrin fragment DInterleukin-17
Identifiers
PMID42308329
PMCPMC13464548
What OpenQuestion holds
Textmetadata
Read underepoch 390